Delving into the Latest Updates on Anhui Shackle Hospital Co., Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Neoplasms

γ-δT

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

γ-δT	1

This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, PFS and OS.

Start Date01 Mar 2024

Sponsor / Collaborator

Shanghai Tongji Hospital

[+11]

100 Clinical Results associated with Anhui Shackle Hospital Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Anhui Shackle Hospital Co., Ltd.

Login to view more data

100 Deals associated with Anhui Shackle Hospital Co., Ltd.

Login to view more data

100 Translational Medicine associated with Anhui Shackle Hospital Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 16 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data